Unilab and Faberco Seal agreement for private sector workers' access to Covid-19 vaccine | Global News

Unilab and Faberco Seal agreement for private sector workers’ access to Covid-19 vaccine

/ 12:01 AM January 25, 2021

Unilab, Inc. (Unilab) and Faberco Life Sciences, Inc. (Faberco) signed an agreement to make Covovax™ vaccine developed by Novavax and manufactured by Serum Institute of India (SII) available to workers and employees of the private sector, subject to approval by the National Task Force Against COVID-19, the Department of Health (DOH) and the Emergency Use Application (EUA) evaluation by the Philippine Vaccine Expert Panel and the Philippine Food and Drug Administration (FDA). Novavax is a company based in Maryland, USA and one of the companies supported by the US government under Operation Warp Speed. SII is the world’s largest vaccine manufacturer.

Under the agreement, Faberco, which is the distributor of Covovax™ vaccines in the Philippines, appointed Unilab as its authorized partner for the private sector.


“Unilab and Faberco share the same vision and advocacy in terms of providing access to as many Filipinos at the soonest possible time.  We are prepared to help the Philippine government in protecting the people by enabling more access to Covid-19 vaccines through the private sector,” says Kishore Hemlani, founder of Faberco.

According to Atty. Jose Maria A. Ochave, Senior Vice President for Social Partnerships of Unilab, “This initiative is not for a business purpose but to help the country secure more vaccine allocations. The vaccines will be made available to the private sector, especially hospitals and essential industries, with the condition that they be made available at no cost to their employees, and, depending on the company’s financial capability, also to their employees’ families and their selected communities. Further, the distribution and administration of the vaccine will be strictly subject to the guidelines set forth by the Department of Health, including those pertaining to pharmacovigilance.”


Faberco is the partner of SII in the Philippines.  SII signed a term sheet with the Philippine government to secure 30 million doses of Covid-19 vaccines.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: COVID-19, Faberco, Unilab, Vaccine
For feedback, complaints, or inquiries, contact us.

Subscribe to our global news

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2022 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.